Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service.
Aged
Anticoagulants
/ adverse effects
Aspirin
/ adverse effects
Clopidogrel
/ adverse effects
Female
Hemorrhage
/ chemically induced
Humans
Middle Aged
Platelet Aggregation Inhibitors
/ adverse effects
Prasugrel Hydrochloride
/ adverse effects
Prospective Studies
Thrombosis
/ prevention & control
Ticagrelor
/ adverse effects
Warfarin
/ adverse effects
Anticoagulation
Antiplatelet therapy
Antithrombotic therapy
Warfarin
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
pubmed:
12
7
2020
medline:
26
10
2021
entrez:
12
7
2020
Statut:
ppublish
Résumé
Patients on long-term anticoagulation combined with antiplatelet therapy have an increased risk of bleeding compared to patients on anticoagulation alone. The aim of this study was to evaluate the appropriateness of antiplatelet therapy in patients who are on long-term warfarin therapy and are managed by Brigham and Women's Hospital Anticoagulation Management Service (BWH AMS). This was a single-center, prospective chart review of patients managed by BWH AMS who were on long-term warfarin therapy plus full-dose aspirin (325 mg), an oral P2Y
Identifiants
pubmed: 32651889
doi: 10.1007/s11239-020-02207-3
pii: 10.1007/s11239-020-02207-3
doi:
Substances chimiques
Anticoagulants
0
Platelet Aggregation Inhibitors
0
Warfarin
5Q7ZVV76EI
Clopidogrel
A74586SNO7
Prasugrel Hydrochloride
G89JQ59I13
Ticagrelor
GLH0314RVC
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
405-412Références
Schafer AI (2008) 50 years in hematology, Chapter 3: platelet and blood clotting. Antithromb Ther Am Soc Hematol 3:28–32
McNeil JJ et al (2018) Effect of aspirin on all-cause mortality in the healthy elderly (ASPREE trial). N Engl J Med 379:1519–1528
doi: 10.1056/NEJMoa1803955
McNeil JJ et al (2018) Effects of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 379:1509–1518
doi: 10.1056/NEJMoa1805819
Ridker PM et al (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352:1293–1304
doi: 10.1056/NEJMoa050613
Vandvik PO et al (2012) Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed. CHEST 141(2):e637S–e668S
doi: 10.1378/chest.11-2306
January CT et al (2019) AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation 140:e125–e151
doi: 10.1161/CIR.0000000000000665
Nishimura RA et al (2017) ACC/AHA focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease. Circulation 135:e1159–e1195
doi: 10.1161/CIR.0000000000000503
Kernan WN et al (2014) Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 45:2160–2236
doi: 10.1161/STR.0000000000000024
Angiolillo DJ et al (2007) Antiplatelet therapy in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 14:124–131
doi: 10.1097/MED.0b013e32807f2ad9
Engstrom PF et al (2009) (2009) Colon Cancer, clinical practice guidelines in oncology. JNCCN 7:778–831
pubmed: 19755046
Dube C et al (2007) The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive service task force. Ann Intern Med 146(5):365–375
doi: 10.7326/0003-4819-146-5-200703060-00009
Levine GN et al (2016) American College of Cardiology (ACC)/American Heart Association (AHA) guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Circulation 134:e123–e155
doi: 10.1161/CIR.0000000000000404
Kirchhof P et al (2016) European Society of Cardiology (ESC): guidelines for the management of atrial fibrillation developed in collaboration with European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 37:2893–2962
doi: 10.1093/eurheartj/ehw210
Dentali F, Douketis JD, Lim W, Crowther M (2007) Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 167:117–124
doi: 10.1001/archinte.167.2.117
Johnson SG, Rogers K, Delate T et al (2008) Outcomes associated with combined antiplatelet and anticoagulant therapy. CHEST 133:948–954
doi: 10.1378/chest.07-2627
Marik PE, Cavallazzi R (2015) Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: a systematic review and meta-analysis. PLoS One 359:143–252
Roldan V et al (2013) The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHADS2-VASc scores in anticoagulated patient with atrial fibrillation. J Am Coll Cardiol
Omran H et al (2012) The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national BNK online bRiDging REgistRy (BORDER). Thromb Haemost 108(1):65–73
doi: 10.1160/TH11-12-0827
Shireman TI, Howard PA, Kresowik TF et al (2004) Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 35:2362–2367
doi: 10.1161/01.STR.0000141933.75462.c2
Turan B, Demir H, Mutlu A et al (2016) Inappropriate combination of warfarin and aspirin. Anatol J Cardiol 16:189–196
pubmed: 26467380
Cannon CP et al (2017) Antithrombotic therapy with dabigatran after PCI in atrial fibrillation (RE-DUAL PCI trial). N Engl J Med 377:1516–1524
doi: 10.1056/NEJMoa1708454
Lopes RD et al (2019) Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation (AUGUSTUS trial). N Engl J Med 380:1509–1524
doi: 10.1056/NEJMoa1817083
Gibson MC et al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI (PIONEER-AF-PCI trial). N Engl J Med 375:2423–2434
doi: 10.1056/NEJMoa1611594
Kaatz S et al (2019) Core elements of anticoagulation stewardship programs. Anticoagulation Forum, 1–21